UK Markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0400+0.6400 (+26.67%)
At close: 12:52PM BST
Full screen
Previous close2.4000
Open2.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4000 - 2.4000
52-week range2.4000 - 2.4000
Volume868
Avg. volumeN/A
Market cap189.616M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021

    STRASBOURG, France & LUND, Sweden, October 01, 2021--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will present additional preclinical data on their novel

  • Business Wire

    Availability of Transgene’s Half-Year Financial Report as of June 30, 2021

    STRASBOURG, France, September 22, 2021--Regulatory News: TRANSGENE (Paris:TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2021.

  • Business Wire

    Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023

    STRASBOURG, France, September 22, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.